AIM ImmunoTech Inc. (AIM) Stock Score, Valuation & Financial Research
AIM ImmunoTech Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 12/100.
Quick answer for AIM
AIM ImmunoTech Inc. currently has a Wall Street Score of 12/100. The stored market price is $0.21. Its financial score is 1/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What AIM ImmunoTech Inc. does
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly
AIM financial snapshot
- Wall Street Score:
- 12/100
- Current price:
- $0.21
- Market capitalization:
- $722K
- Revenue:
- $95K
- Net income:
- $-14.3M
- Free cash flow:
- $-11.3M
- Cash:
- $9.9M
- Total debt:
- $3.9M
- EPS:
- -3.84
- Financial score:
- 1/100
- Valuation score:
- 0/100
- Revenue score:
- 9/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-11.3M, showing cash burn in the current stored period.
- The balance sheet shows $9.9M of cash versus $3.9M of total debt, leaving more cash than debt.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 1/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AIM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.